A need for an individualized approach to end-stage renal disease patients

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 6, 2002, Pages 17-21

  Hörl, Walter H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anaemia; End stage renal disease; Epoetin ; Patient education; Renal insufficiency; Target haemoglobin

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN;

ANEMIA; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; HEART DISEASE; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; PATIENT EDUCATION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; TREATMENT OUTCOME; CHRONIC KIDNEY FAILURE; DRUG ADMINISTRATION; METABOLISM; RENAL REPLACEMENT THERAPY; REVIEW;

ANEMIA; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

EID: 0036319866     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.suppl_6.17     Document Type: Article

References (28)

1. European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure
2. Clinical Practice Guidelines for the treatment of anemia of chronic renal failure
3. Clinical Practice Guidelines for anemia of chronic kidney disease: Update 2000
4. Normalization of haemoglobin: Why not?
5. Higher target haemoglobin level and early anaemia treatment: Different or complementary concepts?
6. Optimal haemoglobin during treatment with recombinant human erythropoietin
7. The optimal target hemoglobin
8. The impact of anemia on cardiomyopathy, morbidity, and mortality in end stage renal disease
9. Outcome and risk factors for left ventricular disorders in chronic uraemia
10. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin
11. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients
12. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients
13. Multidisciplinary predialysis programs: Quantification and limitations of their impact on patient outcomes in two Canadian settings
14. Management of anaemia in United Kingdom renal units: A report from the UK Renal Registry
15. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
16. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy
17. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure
18. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients
19. The CREATE trial - Building the evidence
20. European Best Practice Guidelines 9-13: Anaemia management
21. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration
22. Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients
23. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients
24. Once weekly compared with three times weekly subcutaneous epoetin β, results from a randomized, multicenter, therapeutic equivalence study
25. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β: Results from a randomized controlled multicentre trial
26. The USRDS Dialysis Morbidity and Mortality Study: Wave 2
27. The impact of pre-ESRD education on dialysis modality selection
28. Factors associated with modality selection: Results from the national pre-ESRD education initiative